Menu
Recruiting NCT06898073

Dual-task Training During Curved Walking in Stroke Patients

No phase Interventional Stroke Rehabilitation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: cognitive dual-task group, Single-task group.
Who it may be relevant to
Registry conditions: Stroke Rehabilitation. Basic parameters: 40 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of Dual-task Training During Curved Walking for Cognitive Function in Stroke Patients

Overview

The purpose of this study is to explore the effects of curved walking training under dual-task conditions on the cognitive function and walking ability of stroke patients.

Interventions

  • Behavioral cognitive dual-task group
    Cognitive tasks as the second task in addition to walking
  • Behavioral Single-task group
    walking without performing a second task during the walking training

Primary outcome measures

  • Mini-Mental State Examination [Time frame: From baseline to the end of treatment at 3 weeks]
  • Trail Making Test [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while turning - time [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while turning - numbers of steps [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while turning - gait speed [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while turning - step length [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while turning - step time [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while straight-line walking - time [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while straight-line walking - numbers of steps [Time frame: From baseline to the end of treatment at 3 weeks]
  • Walking ability with different attention loads while straight-line walking - gait speed [Time frame: From baseline to the end of treatment at 3 weeks]
Secondary outcome measures (3)
  • Berg Balance Scale [Time frame: From baseline to the end of treatment at 3 weeks]
  • Activities-Specific Balance Confidence scale [Time frame: From baseline to the end of treatment at 3 weeks]
  • Number of falls [Time frame: From baseline to the end of treatment at 3 weeks]

Eligibility criteria

Inclusion criteria

  • First-time unilateral stroke
  • Age between 40 and 80 years
  • Able to walk 10 meters continuously with or without the use of assistive devices
  • Capable of following instructions and performing simple arithmetic
  • Brunnstrom stage 3 or higher

Exclusion criteria

  • Other neurological disease or unstable medical conditions
  • Visual field defect
  • Mini-Mental State Examination (MMSE) <24 points
  • Pusher syndrome
  • Half-sided neglect
  • Expressive aphasia
  • Poorly controlled hypertension or cardiovascular disease

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Taiwan · 1 center
  • Fooyin University — Kaohsiung City

Identifiers

NCT: NCT06898073 · KSVGH24-CT8-05

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗